175 related articles for article (PubMed ID: 36471019)
21. Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma.
Kim A; Stevenson P; Cassaday RD; Soma L; Fromm JR; Gopal AK; Smith SD; Till B; Lynch RC; Ujjani C; Shadman M; Warren EH; Menon M; Russell K; Tseng YD
Pract Radiat Oncol; 2020; 10(1):44-52. PubMed ID: 31585205
[TBL] [Abstract][Full Text] [Related]
22. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
23. AID is a poor prognostic marker of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.
Miyaoka M; Kikuti YY; Carreras J; Itou A; Ikoma H; Tomita S; Shiraiwa S; Ando K; Nakamura N
Pathol Int; 2022 Jan; 72(1):35-42. PubMed ID: 34727403
[TBL] [Abstract][Full Text] [Related]
24. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.
Takimoto-Shimomura T; Tsukamoto T; Maegawa S; Fujibayashi Y; Matsumura-Kimoto Y; Mizuno Y; Chinen Y; Shimura Y; Mizutani S; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
Invest New Drugs; 2019 Apr; 37(2):210-222. PubMed ID: 29931583
[TBL] [Abstract][Full Text] [Related]
25. Genetics and diffuse large B-Cell lymphoma.
Niroula R; Butera J
R I Med J (2013); 2015 Nov; 98(11):23-6. PubMed ID: 26517251
[TBL] [Abstract][Full Text] [Related]
26. Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation.
Herrera AF; Mei M; Low L; Kim HT; Griffin GK; Song JY; Merryman RW; Bedell V; Pak C; Sun H; Paris T; Stiller T; Brown JR; Budde LE; Chan WC; Chen R; Davids MS; Freedman AS; Fisher DC; Jacobsen ED; Jacobson CA; LaCasce AS; Murata-Collins J; Nademanee AP; Palmer JM; Pihan GA; Pillai R; Popplewell L; Siddiqi T; Sohani AR; Zain J; Rosen ST; Kwak LW; Weinstock DM; Forman SJ; Weisenburger DD; Kim Y; Rodig SJ; Krishnan A; Armand P
J Clin Oncol; 2017 Jan; 35(1):24-31. PubMed ID: 28034071
[TBL] [Abstract][Full Text] [Related]
27. Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
Bojarczuk K; Wienand K; Ryan JA; Chen L; Villalobos-Ortiz M; Mandato E; Stachura J; Letai A; Lawton LN; Chapuy B; Shipp MA
Blood; 2019 Jan; 133(1):70-80. PubMed ID: 30322870
[TBL] [Abstract][Full Text] [Related]
28. Peripheral immune cell profiling of double-hit lymphoma by mass cytometry.
Lei T; Wu G; Xu Y; Zhuang W; Lu J; Han S; Zhuang Y; Dong X; Yang H
BMC Cancer; 2023 Feb; 23(1):184. PubMed ID: 36823603
[TBL] [Abstract][Full Text] [Related]
29. Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma.
Donati G; Ravà M; Filipuzzi M; Nicoli P; Cassina L; Verrecchia A; Doni M; Rodighiero S; Parodi F; Boletta A; Vellano CP; Marszalek JR; Draetta GF; Amati B
Mol Oncol; 2022 Mar; 16(5):1132-1152. PubMed ID: 34632715
[TBL] [Abstract][Full Text] [Related]
30. Fitting double-hit lymphoma into the aggressive lymphoma spectrum: a square peg in a round hole?
Gordon MJ; Westin JR
Leuk Lymphoma; 2022 May; 63(5):1034-1044. PubMed ID: 34842019
[TBL] [Abstract][Full Text] [Related]
31. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
[TBL] [Abstract][Full Text] [Related]
32. Double-Hit Large B Cell Lymphoma.
Khelfa Y; Lebowicz Y; Jamil MO
Curr Oncol Rep; 2017 Sep; 19(11):74. PubMed ID: 28952038
[TBL] [Abstract][Full Text] [Related]
33. Contribution of immunophenotype to the investigation and differential diagnosis of Burkitt lymphoma, double-hit high-grade B-cell lymphoma, and single-hit MYC-rearranged diffuse large B-cell lymphoma.
Tsagarakis NJ; Papadhimitriou SI; Pavlidis D; Liapis K; Gortzolidis G; Kostopoulos IV; Marinakis T; Paterakis G
Cytometry B Clin Cytom; 2020 Sep; 98(5):412-420. PubMed ID: 32497402
[TBL] [Abstract][Full Text] [Related]
34. EBV
Liu H; Xu-Monette ZY; Tang G; Wang W; Kim Y; Yuan J; Li Y; Chen W; Li Y; Fedoriw GY; Zhu F; Fang X; Luedke C; Medeiros LJ; Young KH; Hu S
Histopathology; 2022 Feb; 80(3):575-588. PubMed ID: 34637146
[TBL] [Abstract][Full Text] [Related]
35. ID3 mutations are recurrent events in double-hit B-cell lymphomas.
Gebauer N; Bernard V; Feller AC; Merz H
Anticancer Res; 2013 Nov; 33(11):4771-8. PubMed ID: 24222112
[TBL] [Abstract][Full Text] [Related]
36. MYC/BCL2 double-hit high-grade B-cell lymphoma.
Li S; Lin P; Young KH; Kanagal-Shamanna R; Yin CC; Medeiros LJ
Adv Anat Pathol; 2013 Sep; 20(5):315-26. PubMed ID: 23939148
[TBL] [Abstract][Full Text] [Related]
37. Combined BCL-2 and PI3K/AKT Pathway Inhibition in
Holz C; Lange S; Sekora A; Knuebel G; Krohn S; Murua Escobar H; Junghanss C; Richter A
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674872
[TBL] [Abstract][Full Text] [Related]
38. AMG176, an MCL-1 inhibitor, is active in pre-clinical models of aggressive B-cell lymphomas.
Torka P; Russell T; Mavis C; Gu J; Ghione P; Barth M; Hernandez-Ilizaliturri FJ
Leuk Lymphoma; 2023 Jun; 64(6):1175-1185. PubMed ID: 37074033
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
Ma J; Zhao S; Qiao X; Knight T; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Wang G; Zhao L; Lin H; Wang Y; Taub JW; Ge Y
Clin Cancer Res; 2019 Nov; 25(22):6815-6826. PubMed ID: 31320594
[TBL] [Abstract][Full Text] [Related]
40. Altered pathways and targeted therapy in double hit lymphoma.
Zhuang Y; Che J; Wu M; Guo Y; Xu Y; Dong X; Yang H
J Hematol Oncol; 2022 Mar; 15(1):26. PubMed ID: 35303910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
